vs
bioAffinity Technologies, Inc.（BIAF）与MAXCYTE, INC.（MXCT）财务数据对比。点击上方公司名可切换其他公司
MAXCYTE, INC.的季度营收约是bioAffinity Technologies, Inc.的3.0倍（$4.8M vs $1.6M）。bioAffinity Technologies, Inc.净利率更高（-197.0% vs -200.5%，领先3.5%）。MAXCYTE, INC.同比增速更快（-20.9% vs -27.8%）。bioAffinity Technologies, Inc.自由现金流更多（$-2.6M vs $-2.9M）。过去两年MAXCYTE, INC.的营收复合增速更高（-7.4% vs -18.6%）
bioAffinity Technologies是一家处于临床阶段的生物技术企业，专注于研发可用于癌症、呼吸系统疾病早期检测的非侵入性体外诊断产品，面向全球医疗市场，致力于提供高准确率的便捷诊断方案，改善患者诊疗体验与预后效果。
MaxCyte Inc.是一家全球化生物技术企业，专注于开发细胞工程平台及细胞与基因治疗领域的赋能技术。其专利非病毒细胞修饰系统被制药、生物技术及生命科学研究机构广泛采用，支持免疫疗法、基因编辑疗法及下一代生物药从临床前到商业化的全流程研发。
BIAF vs MXCT — 直观对比
营收规模更大
MXCT
是对方的3.0倍
$1.6M
营收增速更快
MXCT
高出6.9%
-27.8%
净利率更高
BIAF
高出3.5%
-200.5%
自由现金流更多
BIAF
多$360.4K
$-2.9M
两年增速更快
MXCT
近两年复合增速
-18.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6M | $4.8M |
| 净利润 | $-3.1M | $-9.6M |
| 毛利率 | — | — |
| 营业利润率 | -196.9% | -234.5% |
| 净利率 | -197.0% | -200.5% |
| 营收同比 | -27.8% | -20.9% |
| 净利润同比 | -5.7% | 9.4% |
| 每股收益（稀释后） | $-3.59 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIAFMXCT
| Q4 25 | $1.6M | $4.8M | ||
| Q3 25 | $1.4M | $4.6M | ||
| Q2 25 | $1.3M | $5.8M | ||
| Q1 25 | $1.9M | $5.7M | ||
| Q4 24 | $2.2M | $6.1M | ||
| Q3 24 | $2.4M | $5.6M | ||
| Q2 24 | $2.4M | $5.0M | ||
| Q1 24 | $2.4M | $5.6M |
净利润BIAFMXCT
| Q4 25 | $-3.1M | $-9.6M | ||
| Q3 25 | $-5.1M | $-12.4M | ||
| Q2 25 | $-4.1M | $-12.4M | ||
| Q1 25 | $-2.7M | $-10.3M | ||
| Q4 24 | $-3.0M | $-10.6M | ||
| Q3 24 | $-2.0M | $-11.6M | ||
| Q2 24 | $-2.1M | $-9.4M | ||
| Q1 24 | $-2.0M | $-9.5M |
营业利润率BIAFMXCT
| Q4 25 | -196.9% | -234.5% | ||
| Q3 25 | -158.6% | -307.4% | ||
| Q2 25 | -198.2% | -244.3% | ||
| Q1 25 | -141.7% | -214.1% | ||
| Q4 24 | -133.5% | -213.1% | ||
| Q3 24 | -84.0% | -250.4% | ||
| Q2 24 | -87.1% | -241.0% | ||
| Q1 24 | -80.8% | -219.8% |
净利率BIAFMXCT
| Q4 25 | -197.0% | -200.5% | ||
| Q3 25 | -349.3% | -269.7% | ||
| Q2 25 | -319.9% | -212.2% | ||
| Q1 25 | -143.5% | -178.7% | ||
| Q4 24 | -134.4% | -175.0% | ||
| Q3 24 | -85.1% | -205.9% | ||
| Q2 24 | -88.0% | -188.8% | ||
| Q1 24 | -81.5% | -170.6% |
每股收益（稀释后）BIAFMXCT
| Q4 25 | $-3.59 | — | ||
| Q3 25 | $-4.74 | $-0.12 | ||
| Q2 25 | $-0.17 | $-0.12 | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $-17.27 | — | ||
| Q3 24 | $-4.84 | $-0.11 | ||
| Q2 24 | $-0.19 | $-0.09 | ||
| Q1 24 | $-0.20 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.4M | $103.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3M | $171.5M |
| 总资产 | $11.0M | $202.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIAFMXCT
| Q4 25 | $6.4M | $103.0M | ||
| Q3 25 | $7.7M | $105.7M | ||
| Q2 25 | $802.8K | $126.6M | ||
| Q1 25 | $444.7K | $138.3M | ||
| Q4 24 | $1.1M | $154.5M | ||
| Q3 24 | $756.6K | $153.8M | ||
| Q2 24 | $801.3K | $157.3M | ||
| Q1 24 | $2.5M | $157.5M |
股东权益BIAFMXCT
| Q4 25 | $7.3M | $171.5M | ||
| Q3 25 | $8.9M | $180.3M | ||
| Q2 25 | $-2.1M | $190.7M | ||
| Q1 25 | $1.4M | $199.4M | ||
| Q4 24 | $2.6M | $206.3M | ||
| Q3 24 | $3.1M | $213.3M | ||
| Q2 24 | $3.4M | $221.3M | ||
| Q1 24 | $5.3M | $226.4M |
总资产BIAFMXCT
| Q4 25 | $11.0M | $202.5M | ||
| Q3 25 | $11.5M | $213.5M | ||
| Q2 25 | $4.8M | $219.8M | ||
| Q1 25 | $5.5M | $230.0M | ||
| Q4 24 | $6.5M | $239.5M | ||
| Q3 24 | $6.6M | $248.6M | ||
| Q2 24 | $6.7M | $251.5M | ||
| Q1 24 | $8.0M | $257.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.6M | $-2.7M |
| 自由现金流经营现金流 - 资本支出 | $-2.6M | $-2.9M |
| 自由现金流率自由现金流/营收 | -160.7% | -61.0% |
| 资本支出强度资本支出/营收 | 0.0% | 4.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-9.4M | $-36.2M |
8季度趋势，按日历期对齐
经营现金流BIAFMXCT
| Q4 25 | $-2.6M | $-2.7M | ||
| Q3 25 | $-2.5M | $-7.5M | ||
| Q2 25 | $-2.6M | $-9.9M | ||
| Q1 25 | $-1.6M | $-14.4M | ||
| Q4 24 | $-1.7M | $-7.8M | ||
| Q3 24 | $-1.7M | $-4.4M | ||
| Q2 24 | $-1.5M | $-4.8M | ||
| Q1 24 | $-2.3M | $-10.6M |
自由现金流BIAFMXCT
| Q4 25 | $-2.6M | $-2.9M | ||
| Q3 25 | $-2.5M | $-7.8M | ||
| Q2 25 | $-2.7M | $-10.4M | ||
| Q1 25 | $-1.7M | $-15.1M | ||
| Q4 24 | $-1.7M | $-8.0M | ||
| Q3 24 | $-1.7M | $-4.8M | ||
| Q2 24 | $-1.6M | $-5.1M | ||
| Q1 24 | $-2.4M | $-11.4M |
自由现金流率BIAFMXCT
| Q4 25 | -160.7% | -61.0% | ||
| Q3 25 | -171.8% | -168.5% | ||
| Q2 25 | -209.6% | -179.2% | ||
| Q1 25 | -91.3% | -262.3% | ||
| Q4 24 | -76.0% | -131.6% | ||
| Q3 24 | -73.1% | -85.5% | ||
| Q2 24 | -65.1% | -103.3% | ||
| Q1 24 | -99.2% | -203.6% |
资本支出强度BIAFMXCT
| Q4 25 | 0.0% | 4.8% | ||
| Q3 25 | 0.3% | 6.5% | ||
| Q2 25 | 1.1% | 10.0% | ||
| Q1 25 | 2.7% | 11.4% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.4% | 7.2% | ||
| Q2 24 | 1.2% | 5.9% | ||
| Q1 24 | 1.7% | 14.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
